ArticleEBioMedicine2026
Serum aromatic l-amino acid decarboxylase activity as a biomarker for prodromal and manifest Parkinson's disease.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAromatic l-amino acid decarboxylase (AADC), or dopa decarboxylase (DDC), is a key enzyme in levodopa metabolism. Previous studies suggested that AADC protein levels may be increased in Parkinson's disease (PD), particularly if treated with levodopa in conjunction with a peripheral decarboxylase inhibitor (PDI).
methodsSerum AADC enzyme activity was measured by quantifying ex vivo conversion of levodopa to dopamine, and correlated to diagnosis, disease stage and clinical parameters in (i) n = 43 people with probable prodromal PD; (ii) n = 592 people with early PD (≤5 years since diagnosis), of whom n = 116 unmedicated; (iii) n = 48 medicated people with PD with longer disease duration (>5 years); and (iv) n = 74 non-parkinsonian controls.
findingsAADC activity was higher (P < 0.001) in probable prodromal PD (median 44.20 mU/L, IQR 34.30-58.60) and in manifest but unmedicated early PD (median 45.76, IQR 35.50-53.37) than in controls (median 35.09, IQR 26.92-44.49). Although AADC activity increased with disease duration (P < 0.001), there was no difference in AADC activity between probable prodromal and unmedicated manifest PD (P = 0.65). Use of dopaminergic medication increased AADC activity dose-dependently (median AADC in medicated PD: 110.09, IQR 85.44-145.82, P < 0.001).
interpretationPeople with PD have higher serum AADC activity than controls, even in prodromal and unmedicated stages, suggesting a process driven by dopaminergic neurodegeneration. In medicated people with PD, AADC activity is markedly and dose-dependently increased. Results suggest that increased AADC activity could serve as an early biomarker for disease in unmedicated patients and that use of dopaminergic medication paradoxically induces AADC.
fundingThis study was funded by Stichting Alkemade-Keuls. Underlying cohorts were funded by Verily Life Sciences LLC, Radboud University Medical Center, Radboud University, the city of Nijmegen, the Province of Gelderland, ParkinsonNederland, the Dutch Digestive Foundation, Stichting Woelse Waard, Stichting Alkemade-Keuls, the Luxembourg National Research Fund (FNR), and the European Union's Horizon 2020 research and innovation programme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.